• Medacta posted H1 2026 revenue of Euro 368 million, up 7% year on year, while profit for the period fell 30.17% to Euro 41.9 million.
• EBITDA dropped 12.4% to Euro 96.8 million, reflecting a tougher comparison after a prior-year bargain purchase gain tied to Parcus Medical.
• North America revenue was broadly flat at Euro 102 million, while EMEA rose 10.1% to Euro 185 million.
• Hip revenue increased 5.8% to Euro 145 million, while Knee climbed 7.8% to Euro 154 million.
• CEO Francesco Siccardi cited an unexpected softening in the US market; the 2026 outlook for 10%-14% constant-currency revenue growth was reaffirmed.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Medacta Group SA published the original content used to generate this news brief via EQS News (Ref. ID: adhoc_2396082_en) on September 09, 2026, and is solely responsible for the information contained therein.